StockData
Nektar Therapeutics logo

Nektar Therapeutics (NKTR) stock

NKTRNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q4 FY2025, quarter ended Dec 31, 2025Last filing: 10-Q on Nov 13, 2026Score 9/30
$35.91−0.53 (-1.45%)

Close on Nov 17, 2026Market cap $1.23BP/E –Yield –

Nektar Therapeutics enterprise value

Enterprise value is market cap plus debt, minus cash: the value of the whole business to all its investors.

Nektar Therapeutics's enterprise value was $99.02M on Nov 11, 2026, against $1.01B a year earlier. Over the last 5 years it ranged from -$372.98M to $1.57B, with a median of -$20.14M.

Enterprise Value at the end of each year

PeriodPeriod endValueChange
2026Nov 11, 2026$99.02M-82.3%
2025Dec 31, 2025$560.70M–
2024Dec 31, 2024-$72.96M–
2023Dec 29, 2023-$265.83M–
2022Dec 30, 2022-$121.63M-107.7%
2021Dec 31, 2021$1.57B-24.9%
2020Dec 31, 2020$2.09B-8.9%
2019Dec 31, 2019$2.30B-46.1%
2018Dec 31, 2018$4.27B-54.3%
2017Dec 29, 2017$9.33B+473.6%
2016Dec 30, 2016$1.63B-26.9%
2015Dec 31, 2015$2.23B+13.8%
2014Dec 31, 2014$1.96B+56.3%
2013Dec 31, 2013$1.25B+48.5%
2012Dec 31, 2012$842.35M+360.8%
2011Dec 30, 2011$182.79M–

More Nektar Therapeutics figures

See a number that looks wrong?